The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Reflects the Demographics and Subtypes of Patients Diagnosed with Non-Hodgkin Lymphoma in the United States

Conclusions: LEO is a large and diverse cohort of newly diagnosed NHL patients and the first two years of enrollment reflects the broader United States NHL population. Enrollment is ongoing. This unique resource will enable examination of the interactions among a broad array of clinical and molecular factors and their impact on multiple outcomes, to improve prognostication, identify new approaches to improve outcomes and survivorship, and facilitate clinical trials using this infrastructure.DisclosuresFlowers: Acerta: Research Funding; Pharmacyclics/ Janssen: Consultancy; OptumRx: Consultancy; Janssen Pharmaceutical: Research Funding; V Foundation: Research Funding; Burroughs Wellcome Fund: Research Funding; Spectrum: Consultancy; Eastern Cooperative Oncology Group: Research Funding; Abbvie: Consultancy, Research Funding; Bayer: Consultancy; Millennium/Takeda: Research Funding; Abbvie: Research Funding; Celgene: Research Funding; Gilead: Consultancy; BeiGene: Research Funding; Karyopharm: Consultancy; Denovo Biopharma: Consultancy; Genentech/Roche: Consultancy; Gilead: Research Funding; Genentech/Roche: Research Funding; National Cancer Institute: Research Funding; TG Therapeutics: Research Funding; Pharmacyclics: Research Funding. Nastoupil: TG Therappeutics: Research Funding; Merck: Honoraria, Research Funding; Celgene: Honoraria, Research Funding; Janssen: Research Funding; Spectrum: Honoraria; Gilead: Honoraria; Genentech: Honoraria, Research Funding; Karus: Research Fund...
Source: Blood - Category: Hematology Authors: Tags: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)-Results from Retrospective/Observational Studies: Poster I Source Type: research

Related Links:

Authors: Wu R, Li XY, Wang WH, Cai FF, Chen XL, Yang MD, Pan QS, Chen QL, Zhou RY, Su SB Abstract To investigate the mechanism of a Bushen-Jianpi decoction (BSJPD) in liver cancer (LC) treatment, we analyzed clinical therapy data, conducted network pharmacology analysis, and performed pharmacological experimental verification in vitro and in vivo. The univariate analysis of clinical therapy showed that the BSJPD was protective factor (p
Source: Evidence-based Complementary and Alternative Medicine - Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research
Effects of Huanglian-Renshen-Decoction, a Fixed Mixture of Traditional Chinese Medicine, on the Improvement of Glucose Metabolism by Maintenance of Pancreatic β Cell Identity in db/db Mice. Evid Based Complement Alternat Med. 2019;2019:1232913 Authors: Yuan F, Wang D, Ma L, Qin X, Gong J, Hu M, Su H, Dong H, Lu F Abstract Huanglian-Renshen-Decoction (HRD) is widely used to treat type 2 diabetes mellitus (T2DM) in China. However, the underlying mechanism is unclear. We aimed to investigate the mechanism by which HRD regulates the glucose level. Forty 7-8-week-old db/db (BSK) mice were randomly assi...
Source: Evidence-based Complementary and Alternative Medicine - Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research
Authors: Yadav GK, Pahwa M, Singh M, Tyagi V, Chadha S Abstract Testosterone deficiency syndrome (TDS) is a gradual age-related phenomenon that occurs in a large proportion of the aging male population. This current prospective study was done with the objective to estimate the prevalence of age-associated TDS in India and its clinical profile. A total of 800 male patients aged ≥40 year were approached to participate in the study. A brief history and focused examination was done. Based on our exclusion criteria, 55 patients were excluded. Androgen deficiency in aging male (ADAM) questionnaire was administe...
Source: Advances in Urology - Category: Urology & Nephrology Tags: Adv Urol Source Type: research
Abstract PURPOSE: To assess the nationwide rate of acute postoperative endophthalmitis (APE) after cataract extraction in Korea and to evaluate potential risk factors thereof. MATERIALS AND METHODS: Nationwide insurance claims data from July 2014 to June 2017 were reviewed. All patients with phacoemulsification or extracapsular/intracapsular cataract extraction were included. Exclusion criteria were combined glaucoma surgery or total vitrectomy or when the patient had a history of intraocular foreign body. RESULTS: In total, 1505103 cases (982203 patients) were included. APE developed in 953 cases (938 p...
Source: Yonsei Medical Journal - Category: Universities & Medical Training Authors: Tags: Yonsei Med J Source Type: research
CONCLUSION: miR-362 may be a prognostic marker in CRC and suppress CRC cell proliferation and invasion in part through targeting the 3'-UTR of SIX1 mRNA. The newly identified miR-362/SIX1 axis provides insight into the progression of CRC. PMID: 31016902 [PubMed - in process]
Source: Yonsei Medical Journal - Category: Universities & Medical Training Authors: Tags: Yonsei Med J Source Type: research
Publication date: Available online 25 April 2019Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): D.M. Monti, G. Ferraro, A. MerlinoAbstractThe encapsulation of anticancer metal-based drugs within a protein nanocage represents a valuable strategy to improve the efficacy and selectivity of these compounds towards cancer cells. The preparation, characterization of the in vitro cytotoxicity and X-ray structures of several ferritin-metallodrug nanocomposites (mainly containing platinum-, ruthenium- and gold-based anticancer agents) are here reviewed. The molecular mechanisms of action of these Ft-metallodrug...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - Category: Nanotechnology Source Type: research
In conclusion, our studies suggest that silica nanoparticles can mediate the delivery of miR-34a directly into mammary tumors while preserving its molecular and biological activity.Graphical AbstractmiR-34a is efficiently delivered by SiO2 nanoparticles and it inhibits tumor growth.
Source: Nanomedicine: Nanotechnology, Biology and Medicine - Category: Nanotechnology Source Type: research
Publication date: Available online 25 April 2019Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Zhijian Luo, Mingxing Li, Meiling Zhou, Huayun Li, Youyou Chen, Xiaoqun Ren, Yan DaiAbstractHerein, a novel nano-system IF7-ROSPCNP, which is O2-evolving and reactive oxygen species (ROS)-activable, was developed for enhancing the combination chemotherapy and photodynamic therapy (PDT). The nanoparticles composed of photosensitizers (disulfonated meso-tetraphenylporphine, TPPS2a) and catalase in the inner core, doxorubicin (DOX) in the polymeric shell and functionalized on its surface with IF7 peptide, which...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - Category: Nanotechnology Source Type: research
Publication date: Available online 25 April 2019Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Ci Ren, Xiaomin Li, Lu Mao, Jinfeng Xiong, Chun Gao, Hui Shen, Liming Wang, Da Zhu, Wencheng Ding, Hui WangAbstractGene therapy targeted human papillomavirus (HPV) is a promising treatment for cervical cancer, and the key for clinical application depends on an effective gene delivery method. Our aim was to formulate a new pharmaceutical formula for appropriate gene delivery intravaginally. For the first time, we here developed a new polyethylenimine (PEI) based vaginal suppository. The sectional immunofluore...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - Category: Nanotechnology Source Type: research
In conclusion, the proposed framework is suit for multi-classification tasks of gastric M-NBI images.
Source: Neurocomputing - Category: Neuroscience Source Type: research
More News: AstraZeneca | Autoimmune Disease | Cancer | Cancer & Oncology | Cancer Therapy | Cardiology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Clinical Trials | Diabetes | Endocrinology | Epidemiology | Genetics | Heart | Heart Disease | Hodgkin's Disease | Leukemia | Lymphoma | Merck | Nanotechnology | Non-Hodgkin's Lymphoma | Orthopaedics | Osteoporosis | Pathology | Pfizer | Pharmaceuticals | Study | USA Health | Washington University